Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open Label Study Comparing Safety and Efficacy Parameters for a High and a Low Dose of Ambrisentan (Adjusted for Body Weight) for the Treatment of Pulmonary Arterial Hypertension in Paediatric Patients Aged 8 Years up to 18 Years

NCT01332331 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01332331
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01332331 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open Label Study Comparing Safety and Efficacy Parameters for a High and a Low Dose of Ambrisentan (Adjusted for Body Weight) for the Treatment of Pulmonary Arterial Hypertension in Paediatric Patients Aged 8 Years up to 18 Years
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Terminated
Start date
January 4, 2011
Completion date
November 12, 2013
Enrollment
41 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension, pulmonary